{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:09:33Z","timestamp":1790388573729,"version":"4.1.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":549,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1111\/bjd.12690","type":"journal-article","created":{"date-parts":[[2014,1,17]],"date-time":"2014-01-17T14:14:44Z","timestamp":1389968084000},"page":"720-724","source":"Crossref","is-referenced-by-count":100,"title":["Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas"],"prefix":"10.1093","volume":"170","author":[{"given":"A.","family":"de Masson","sequence":"first","affiliation":[{"name":"Service de Dermatologie; AP-HP; H\u00f4pital Saint-Louis; 1 Avenue Claude Vellefaux 75010 Paris France"},{"name":"INSERM UMR-S976; \u2018Immunologie, Dermatologie, Oncologie\u2019; Universit\u00e9 Paris VII; 1 Avenue Claude Vellefaux 75010 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Guitera","sequence":"additional","affiliation":[{"name":"Service de Dermatologie; AP-HP; H\u00f4pital Saint-Louis; 1 Avenue Claude Vellefaux 75010 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Brice","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie-Oncologie; AP-HP; H\u00f4pital Saint-Louis; 1 Avenue Claude Vellefaux 75010 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Moulonguet","sequence":"additional","affiliation":[{"name":"Service de Dermatologie; AP-HP; H\u00f4pital Saint-Louis; 1 Avenue Claude Vellefaux 75010 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mouly","sequence":"additional","affiliation":[{"name":"Service de Dermatologie; AP-HP; H\u00f4pital Saint-Louis; 1 Avenue Claude Vellefaux 75010 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-D.","family":"Bouaziz","sequence":"additional","affiliation":[{"name":"Service de Dermatologie; AP-HP; H\u00f4pital Saint-Louis; 1 Avenue Claude Vellefaux 75010 Paris France"},{"name":"INSERM UMR-S976; \u2018Immunologie, Dermatologie, Oncologie\u2019; Universit\u00e9 Paris VII; 1 Avenue Claude Vellefaux 75010 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Battistella","sequence":"additional","affiliation":[{"name":"Laboratoire de Pathologie; AP-HP; H\u00f4pital Saint-Louis; 1 Avenue Claude Vellefaux 75010 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Madelaine","sequence":"additional","affiliation":[{"name":"Service de Pharmacie; AP-HP; H\u00f4pital Saint-Louis; 1 Avenue Claude Vellefaux 75010 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Roux","sequence":"additional","affiliation":[{"name":"Service de Dermatologie; AP-HP; H\u00f4pital Saint-Louis; 1 Avenue Claude Vellefaux 75010 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ram-Wolff","sequence":"additional","affiliation":[{"name":"Service de Dermatologie; AP-HP; H\u00f4pital Saint-Louis; 1 Avenue Claude Vellefaux 75010 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-M.","family":"Cayuela","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Biologique; AP-HP; H\u00f4pital Saint-Louis; 1 Avenue Claude Vellefaux 75010 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Bachelez","sequence":"additional","affiliation":[{"name":"Service de Dermatologie; AP-HP; H\u00f4pital Saint-Louis; 1 Avenue Claude Vellefaux 75010 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bensussan","sequence":"additional","affiliation":[{"name":"INSERM UMR-S976; \u2018Immunologie, Dermatologie, Oncologie\u2019; Universit\u00e9 Paris VII; 1 Avenue Claude Vellefaux 75010 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Michel","sequence":"additional","affiliation":[{"name":"INSERM UMR-S976; \u2018Immunologie, Dermatologie, Oncologie\u2019; Universit\u00e9 Paris VII; 1 Avenue Claude Vellefaux 75010 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bagot","sequence":"additional","affiliation":[{"name":"Service de Dermatologie; AP-HP; H\u00f4pital Saint-Louis; 1 Avenue Claude Vellefaux 75010 Paris France"},{"name":"INSERM UMR-S976; \u2018Immunologie, Dermatologie, Oncologie\u2019; Universit\u00e9 Paris VII; 1 Avenue Claude Vellefaux 75010 Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,3,12]]},"reference":[{"key":"10.1111\/bjd.12690-BIB0001|bjd12690-cit-0001","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/j.1365-2133.2006.07264.x","article-title":"Relative frequency and survival of patients with primary cutaneous lymphomas: data from a single-centre study of 203 patients","volume":"154","author":"Bouaziz","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12690-BIB0002|bjd12690-cit-0002","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1034\/j.1600-0609.2003.00143.x","article-title":"Treatment of patients with advanced mycosis fungoides and S\u00e9zary syndrome with alemtuzumab","volume":"71","author":"Kennedy","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1111\/bjd.12690-BIB0003|bjd12690-cit-0003","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"key":"10.1111\/bjd.12690-BIB0004|bjd12690-cit-0004","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/S\u00e9zary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"10.1111\/bjd.12690-BIB0005|bjd12690-cit-0005","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.11127","article-title":"Low-dose intermittent alemtuzumab in the treatment of S\u00e9zary syndrome: clinical and immunologic findings in 14 patients","volume":"92","author":"Bernengo","year":"2007","journal-title":"Haematologica"},{"key":"10.1111\/bjd.12690-BIB0006|bjd12690-cit-0006","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3109\/10428190903216770","article-title":"Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center","volume":"50","author":"Querfeld","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1111\/bjd.12690-BIB0007|bjd12690-cit-0007","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and S\u00e9zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.1111\/bjd.12690-BIB0008|bjd12690-cit-0008","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1111\/bjd.12690-BIB0009|bjd12690-cit-0009","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood-2011-09-379156","article-title":"Inducible expression and pathophysiologic functions of T-plastin in cutaneous T-cell lymphoma","volume":"120","author":"B\u00e9gu\u00e9","year":"2012","journal-title":"Blood"},{"key":"10.1111\/bjd.12690-BIB0010|bjd12690-cit-0010","unstructured":"National Cancer Institute Common terminology criteria for adverse events http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"key":"10.1111\/bjd.12690-BIB0011|bjd12690-cit-0011","doi-asserted-by":"crossref","first-page":"117ra7","DOI":"10.1126\/scitranslmed.3003008","article-title":"Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients","volume":"4","author":"Clark","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1111\/bjd.12690-BIB0012|bjd12690-cit-0012","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.0022-202X.2005.23914.x","article-title":"Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in S\u00e9zary syndrome patients","volume":"125","author":"Bouaziz","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.12690-BIB0013|bjd12690-cit-0013","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/sj.leu.2404435","article-title":"Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation","volume":"20","author":"Karlsson","year":"2006","journal-title":"Leukemia"},{"key":"10.1111\/bjd.12690-BIB0014|bjd12690-cit-0014","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1365-2133.2007.08130.x","article-title":"Acute cutaneous T-cell lymphoma transformation during treatment with alemtuzumab","volume":"157","author":"Faguer","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12690-BIB0015|bjd12690-cit-0015","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","article-title":"Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S\u00e9zary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Duarte","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.12690","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.12690\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:07:25Z","timestamp":1676383645000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/170\/3\/720\/6614797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.12690","relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}